73889-19-7

Basic information

• Product Name: 1-BENZYL-4-(N-BOC-AMINO) PIPERIDINE 98
• Synonyms: 1-BENZYL-4-(N-BOC-AMINO) PIPERIDINE 98;1-Benzyl-4-(N-Boc-amino)piperidine;(1-Benzyl-piperidin-4-yl)-carbamic acid tert-butyl ester;tert-butyl N-(1-benzylpiperidin-4-yl)carbamate;4-Boc-aMino-1-benzylpiperidine;N-Benzyl-4-(N-Boc-aMino)piperidine;tert-Butyl 1-benzylpiperidin-4-ylcarbamate;4-(N-Boc-aMino)-1-benzyl-piperidine
• CAS NO: 73889-19-7
• Molecular Formula: C₁₇H₂₆N₂O₂
• Molecular Weight: 290.404
• Product Categories: Amines and Anilines;Heterocycles;Building Blocks;Heterocyclic Building Blocks;Piperidines
• Mol File: 73889-19-7.mol
• Article Data: 49

Chemical Properties

• Melting Point: 122-125 °C(lit.)
• Boiling Point: 400.9 °C at 760 mmHg
• Flash Point: 196.2 °C
• Appearance: /
• Density: 1.07 g/cm³
• Vapor Pressure: 1.23E-06mmHg at 25°C
• Refractive Index: 1.542
• Storage Temp.: 2-8°C
• PKA: 12.35±0.20(Predicted)
• CAS DataBase Reference: 1-BENZYL-4-(N-BOC-AMINO) PIPERIDINE 98(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-4-(N-BOC-AMINO) PIPERIDINE 98(73889-19-7)
• EPA Substance Registry System: 1-BENZYL-4-(N-BOC-AMINO) PIPERIDINE 98(73889-19-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 73889-19-7(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C17H26N2O2/c1-17(2,3)21-16(20)18-15-9-11-19(12-10-15)13-14-7-5-4-6-8-14/h4-8,15H,9-13H2,1-3H3,(H,18,20)

Upstream product

• 50541-93-0 4-amino-1-benzylpiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 75-09-2 dichloromethane 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 1538-75-6 2,2-dimethylpropanoic anhydride 
• 100-39-0 benzyl bromide 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 100-44-7 benzyl chloride 
• 100-52-7 benzaldehyde 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 2247-88-3 3-fluoro-pyridin-4-ylamine 
• 1260683-20-2 tert-butyl (3-fluoropyridin-4-yl)carbamate 
• 73874-95-0 tert-butyl N-(piperidin-4-yl)carbamate hydrochloride 

Downstream Products

• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 7006-50-0 1-benzyl-N-methylpiperidin-4-amine 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 657401-67-7 2-(4-tert-butoxycarbonylaminopiperidine-1-carbonyl)pyrrolidine-1-carboxylic acid benzyl ester 
• 287399-47-7 butyl 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-1-piperidineacetate 
• 287399-62-6 butyl 4-amino-1-piperidineacetate 
• 287399-61-5 butyl 4-tert-butoxycarbonylamino-1-piperidineacetate 
• 303763-39-5 4-(tert-butoxycarbonylamino)-1-[(6-aminopyridin-2-yl)methyl]piperidine 
• 203321-88-4 (2R)-N-[1-(6-Aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide 
• 303763-38-4 {1-[6-(benzhydrylidene-amino)-pyridin-2-ylmethyl]-piperidin-4-yl}-carbamic acid tert-butyl ester 
• 108612-54-0 tert-butyl methyl(piperidin-4-yl)carbamate 
• 139062-92-3 N-tert-Butoxycarbonyl-N-methyl-1-benzyl-4-piperidinamine 

Relevant articles and documents

Design and development of novel thiazole-sulfonamide derivatives as a protective agent against diabetic cataract in Wistar rats via inhibition of aldose reductase

In recent years, ALR2 (aldose reductase) inhibitors have attracted attention for their effective ability to reduce the progression of diabetes-associated cataracts. Therefore, in the present article, we intended to develop novel thiazole-sulfonamide hybrids as a potent inhibitor of ALR2. These molecules significantly inhibited the ALR2 level in the rat lenses homogenate, where the most potent compound 7b showed activity comparable to sorbinil as standard. In Wistar rats, compound 7b improved the insulin level and body weight of the experimental animal together with a reduction in the glucose output. Compound 7b showed a significant reduction in the expression of ALR2 in rat lenses in western blot analysis.

Nitrogen heterocyclic compound, pharmaceutical composition containing nitrogen heterocyclic compound, and preparation method and application of nitrogen heterocyclic compound

Disclosed are a nitrogen heterocyclic compound represented by a formula (I), a pharmaceutical composition comprising the same, and a preparation method and use of the nitrogen heterocyclic compound, and in particular, relates to the use of the nitrogen heterocyclic compound for prevention or treatment of diseases or conditions associated with RET activity.

Development of the Convergent, Kilogram-Scale Synthesis of an Antibacterial Clinical Candidate Using Enantioselective Hydrogenation

Early chemical development studies into the best way of assembling AZD9742, an antibacterial drug candidate, have involved swapping the order of two reductive aminations. The orthogonally functionalized aminopiperidine partner for these couplings is now enantioselectively synthesized using ruthenium-catalyzed asymmetric hydrogenation. The challenge of controlling defluorination through an appropriate catalyst choice has hitherto prevented this revised sequence from reaching its full potential. However, it is still shown to allow access to the active pharmaceutical ingredient in a stereochemically pure form and has been demonstrated on a multikilogram scale. The reductive aminations in both the original and revised sequences provided different scale-up challenges, and the solutions implemented are described.